Longevity Evidence Lab Human evidence, uncertainty intact
Research interpretation, not diagnosis or personal treatment advice. Urgent symptoms belong with a clinician, not a browser tab.
Home / Evidence / N-acetylcysteine (NAC)
Antioxidant precursor and medicine

N-acetylcysteine (NAC)

Established clinical uses do not automatically translate into routine longevity benefit.

The 30-second verdict NAC is a medicine in some settings and a supplement in others. It is an established antidote for paracetamol poisoning and a mucolytic, with additional research across respiratory, psychiatric and metabolic conditions. Evidence that routine NAC supplementation slows ageing in healthy people is absent.

Evidence matrix

These scores describe different evidence domains. A strong mechanism cannot compensate for missing human outcomes, and a useful clinical effect need not imply slower biological ageing.

Human clinical outcomes Moderate
Human biomarkers Moderate
Animal lifespan Preliminary
Mechanistic plausibility Strong
Safety certainty Moderate
Direct longevity relevance None

What has been shown in humans?

Condition-specific trials sometimes report benefit, but outcomes vary and should be separated from general antioxidant marketing. The GlyNAC literature is relevant but cannot be treated as NAC-only evidence.

What remains uncertain?

Long-term use in healthy adults, effects on training adaptations, ideal target populations and interaction with disease treatments remain uncertain.

Doses used in research

Descriptive, not prescriptive Clinical and supplement studies use very different regimens. Hospital antidote protocols must never be confused with ordinary oral supplementation.

Safety and interpretation

  • Oral NAC commonly causes nausea, reflux or diarrhoea in some people.
  • It can interact with nitrates and may be unsuitable around certain treatments or procedures.
  • Active cancer treatment, anticoagulation and complex medical conditions require clinician or pharmacist input.

Primary sources and evidence reviews

Editorial note

This dossier was last reviewed on 13 July 2026. Ratings can change when larger trials, adverse-event data or better systematic reviews appear. Corrections should alter the page rather than being buried in a social-media thread.